Cefalexin degrading bacterium AB-1 and application thereof
By screening and culturing cefalexin degrading bacteria AB-1, the problem of difficult degradation of antibiotic pollution is solved, and efficient degradation of cefalexin is achieved, providing a green and safe degradation pathway, reducing costs and reducing pollution.
Patent Information
- Application Number
- CN202410998259.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively degrade antibiotic pollution, especially cefalexin. Traditional physical and chemical methods have problems with incomplete degradation and possible secondary pollution, and lack safe, efficient and low-cost microbial degradation methods.
Through modern microbial technology, a cefalexin-degrading bacteria AB-1 (Escherichia coli AB-1) was screened and cultivated. This strain was able to efficiently degrade cefalexin in MSM medium and fecal sewage, with degradation rates reaching 99.98% and 99.73% respectively. In 72 hours and 6 hours.
It provides a green, safe and efficient antibiotic degradation pathway, reduces environmental pollution and health hazards, bioremediation of farms and polluted water bodies, and reduces enterprise treatment costs.
Smart Images

Figure CN118956655A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antibiotic pollution treatment, and more specifically, to a cephalexin-degrading bacterium AB-1 and application thereof. Background Art
[0002] my country is a major producer and consumer of antibiotics. Among all antibiotics, β-lactam antibiotics, such as cephalexin, have the highest consumption. It is the most widely used class of antibiotics in clinical practice since the discovery of antibiotics.
[0003] However, most antibiotics are not absorbed by humans and animals, but enter the environment through metabolic waste, causing serious pollution of soil and water environment. In the process of degrading antibiotics by traditional methods such as physical and chemical methods, there are problems such as incomplete degradation of antibiotics and possible secondary pollution. Bioremediation has a high degradation rate, low cost and will not cause secondary pollution.
[0004] In farms that have been using antibiotics for a long time, there are strains that are tolerant to and able to degrade antibiotics. These strains with degradation capabilities will become good materials for degrading cephalexin.
[0005] However, there are currently very few reports on the microbial-mediated degradation pathway of cephalexin, so there is an urgent need to establish a safe, efficient and low-cost method for microbial degradation of cephalexin.
[0006] To this end, the present invention aims to provide a cephalexin-degrading bacterium AB-1 and its application to solve the above problems. Summary of the invention
[0007] The purpose of the present invention is to provide a cephalexin-degrading bacterium AB-1 and an application thereof. The present invention adopts modern microbial technology, screens and cultivates strains, and finally cultivates a strain capable of efficiently degrading cephalexin. The strain can be used for harmless treatment of residual antibiotics in farm manure or bioremediation of water and soil contaminated by antibiotics, and can reduce the pollution of antibiotic residues to the environment and the health hazards to animals and humans, thereby providing a green, safe and efficient new antibiotic degradation pathway for related enterprises and significantly reducing the cost of antibiotic treatment for enterprises.
[0008] The above technical purpose of the present invention is achieved through the following technical scheme: a cephalexin-degrading bacterium AB-1 and its application, the Latin name of the cephalexin-degrading bacterium AB-1 is Escherichia coli AB-1, the preservation number is CCTCC NO: M 20241312, and it was preserved in the China Center for Type Culture Collection on June 19, 2024, address: Room 211, China Center for Type Culture Collection, Wuhan University, Wuchang District, Wuhan City, Hubei Province.
[0009] The present invention is further configured as follows: the cephalexin-degrading bacteria AB-1 is Escherichia coli AB-1.
[0010] The present invention also provides application of a cephalexin-degrading bacterium AB-1 in degrading cephalexin.
[0011] The present invention also provides use of a cephalexin-degrading bacterium AB-1 in preparing a cephalexin agent.
[0012] The present invention also provides application of a cephalexin-degrading bacterium AB-1 in repairing an environment contaminated by cephalexin.
[0013] The present invention is further configured as follows: a strain of the cephalexin-degrading bacteria AB-1 is used to degrade cephalexin remaining in farm manure.
[0014] In summary, the present invention has the following beneficial effects:
[0015] 1. The present invention adopts modern microbial technology, screens and cultivates strains, and finally cultivates strains that can efficiently degrade cephalexin, and the screened and cultivated cephalexin-degrading bacteria AB-1 have a good effect on cephalexin in MSM culture medium and fecal sewage. Specifically, in MSM culture medium, the degradation rate of cephalexin by cephalexin-degrading bacteria AB-1 can reach 99.98% within 72 hours, and in fecal sewage, the degradation rate of cephalexin by cephalexin-degrading bacteria AB-1 can reach 99.73% within 6 hours;
[0016] 2. The cephalexin-degrading bacteria AB-1 cultivated by the present invention can be used for the harmless treatment of residual antibiotics in farm manure, or for the bioremediation of water and soil contaminated by antibiotics, which can reduce the pollution of antibiotic residues to the environment and the health hazards to animals and humans, and provide related enterprises with a green, safe and efficient new antibiotic degradation pathway, while significantly reducing the cost of antibiotic treatment for enterprises. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 is a molecular structural formula diagram of cephalexin in Example 1 of the present invention;
[0018] Figure 2 is the HPLC spectrum of cephalexin in Example 1 of the present invention;
[0019] Figure 3 is a colony photograph of the cephalexin-degrading bacteria AB-1 in Example 1 of the present invention and a Gram staining microscopic examination of the strain;
[0020] Figure 4is a phylogenetic tree of the 16S rDNA sequence of the cephalexin-degrading bacteria AB-1 in Example 1 of the present invention;
[0021] Figure 5 It is a degradation curve diagram showing the degradation rate of cephalexin changing with time in Example 3 of the present invention. DETAILED DESCRIPTION
[0022] The following is combined with Figure 1-5 The present invention is described in further detail.
[0023] Example 1: A method for screening a cephalexin-degrading bacterium AB-1, comprising the following steps:
[0024] S1. Enrichment and domestication of cephalexin-resistant bacteria: Use a cephalexin screening medium containing an initial concentration of 25 mg / L to screen strains from a suspension of feces samples from a farm that has long used cephalexin (the feces samples in this embodiment were collected from a pig farm that has long used cephalexin in Shihezi City, Xinjiang). Transfer to a screening medium with cephalexin concentrations of 25 mg / L, 50 mg / L, 100 mg / L, 150 mg / L, and 200 mg / L, enrich and culture and domesticate to obtain a cephalexin-resistant strain;
[0025] S2. Isolation and purification of cephalexin-resistant bacteria: The cephalexin-resistant strains obtained by domestication were used to prepare bacterial suspensions, which were diluted to 10 -6 , 10 -7 , 10 -8 and 10 -9 times dilution, and then the strain was separated and purified by the coating method to obtain a single cephalexin-tolerant strain;
[0026] S3. Screening of cephalexin-degrading bacteria: The isolated and purified cephalexin-tolerant single strain was inoculated into a culture medium containing cephalexin for degradation experiment screening, and cephalexin-degrading bacteria AB-1 capable of degrading cephalexin in the culture medium was obtained, which was identified as Escherichia coli AB-1 by 16S rDNA.
[0027] The present embodiment preferably uses the method for removing cephalexin using cephalexin-degrading bacteria AB-1, comprising the following steps: activating the cephalexin-degrading bacteria, inoculating the bacteria in LB medium, and culturing at 180 rpm for 12 h in a constant temperature shaker at 37 ° C to obtain a seed solution, inoculating the seed solution into an MSM medium containing cephalexin for culturing, wherein the pH is 6.0 to 9.0, and the culture temperature is 28 to 40 ° C, which can achieve rapid degradation and removal of the antibiotic cephalexin.
[0028] In this embodiment, preferably, the cephalexin degrading bacteria AB-1 is used to prepare the cephalexin bacterial agent, including the following steps: inoculating the cephalexin degrading bacteria in LB liquid culture medium, culturing in a shaker at 180rpm for 12-24h at 37°C, and collecting the culture fluid to obtain the bacterial agent; specifically including the separation, purification, screening and identification of the cephalexin degrading bacteria AB-1. The specific process of separation and purification of the cephalexin degrading bacteria AB-1 is as follows: weigh 5g of manure collected from a pig farm in Shihezi City that has been using cephalexin for a long time into 50mL of liquid culture medium, place a shaker, adjust the temperature to 37°C, and culture at 180rpm for 12-24h to obtain an enriched domesticated suspension. The liquid culture medium components are: 5g / L yeast powder, 10g / L peptone, 10g / L sodium chloride, sterilized at 121°C for 20min, and cooled to room temperature.
[0029] The suspension was inoculated into an inorganic salt liquid medium (MSM medium) containing 25 mg / L cephalexin at an inoculum size of 5%, placed in a shaker, the temperature was adjusted to 37°C, and cultured at 180 rpm in the dark for 72 hours before cyclic transfer. In each subsequent transfer, the concentration of cephalexin in the culture medium was 25 mg / L, 50 mg / L, 100 mg / L, and 200 mg / L, and finally the tolerant bacterial culture solution was obtained by enrichment and domestication.
[0030] The tolerant bacterial culture solution obtained by domestication was diluted to 10 -6 , 10 -7 , 10 -8 and 10 -9 times, and then spread it on the plate containing cephalexin. The method for making the plate containing cephalexin is: 5g / L yeast powder, 10g / L peptone, 10g / L sodium chloride, 15-20g / L agar powder, sterilize at 121℃ for 20min, cool to about 60℃, add cephalexin mother solution, so that the antibiotic concentration in the solid plate reaches 200mg / L, and then pour the plate in the clean bench. Place the coated plate in an incubator at 37℃ and culture in the dark for 48h to obtain a purified single colony, and then purify the single colony by streaking the plate. The morphology of the purified Escherichia coli AB-1 on solid culture medium and Gram staining microscopy is as follows Figure 3 shown.
[0031] The specific process of screening and identification of cephalexin-degrading bacteria AB-1 is as follows: the purified strain colony is inoculated into a liquid culture medium, and the seed liquid is obtained after culturing at 37°C and 180rpm for 24h. The seed liquid is inoculated into a culture medium containing 100mg / L of cephalexin at an inoculum amount of 5%, and then the bacterial liquid obtained after culturing in the dark at 37°C and 180rpm for 24 is centrifuged at 5000r for 10min. After filtering the supernatant with a 0.22μm filter membrane, the cephalexin content in the supernatant is determined using an ultra-high performance liquid chromatography, and then the degradation rate of the strain to cephalexin is calculated, and finally the strain with high degradation efficiency is screened out.
[0032] The bacterial genome extraction kit was used to extract the genomic DNA of the strain and then PCR amplify its 16S rDNA gene. The upstream and downstream primers of 16S rDNA were both universal bacterial primers. Finally, the obtained PCR product was electrophoresed on 1% agarose gel. According to the results of electrophoresis, the PCR product was sent to Beijing Ruibo Biotechnology Co., Ltd. for DNA sequencing to obtain its 16S rDNA sequence. Then, the sequence was compared with the NCBI database. The comparison results showed that the bacteria belonged to the genus Escherichia coli. Its phylogenetic tree is as follows: Figure 4 shown.
[0033] Example 2: Experiment on the degradation effect of strain AB-1 on cephalexin in MSM medium
[0034] In this example, cephalexin with a final concentration of 100 mg / L was added to the MSM medium, and the inoculum was inoculated into the bacterial solution of the strain AB-1 at a volume ratio of 5%; at the same time, cephalexin with a final concentration of 100 mg / L was added to the MSM medium, and the inactivated bacterial solution was inoculated at the same volume ratio as a control, and the mixture was placed in a constant temperature shaker at 37° C. and 180 rpm for 72 hours. The degradation of cephalexin by the strain AB-1 was detected by ultra-high performance liquid chromatography, and the degradation rate was calculated. The calculation formula of the cephalexin degradation rate is as follows:
[0035] Degradation rate (%) = (C0-C X ) / C0×100%;
[0036] Among them, C0 and C X They represent the concentrations of the control sample and the microorganism-treated sample respectively. It was calculated that the degradation rate of cephalexin by strain AB-1 was 99.98% within 72 hours.
[0037] Example 3: Experimental study on the degradation effect of strain AB-1 on cephalexin in farm fecal wastewater
[0038] In this example, several portions of farm fecal wastewater were weighed, and cephalexin was added to adjust the final concentration to 200 mg / L; the bacterial solution of strain AB-1 was added to the treatment group at a mass ratio of 5%, and a control group without strain AB-1 was set up at the same time, and the mixture was placed in a 37°C incubator for constant temperature culture, during which the water content was maintained at 60%. Each group was subjected to three parallel experiments, and the residual amount of cephalexin was determined by ultra-performance liquid chromatography-mass spectrometry, and the average degradation rate was calculated. The degradation curve is shown in FIG. Figure 5 As shown, the results showed that the degradation rate of cephalexin reached 99.73% within 6 hours.
[0039] This specific embodiment is merely an explanation of the present invention and is not a limitation of the present invention. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed. However, as long as they are within the scope of the claims of the present invention, they are protected by the patent law.
Claims
1. A cephalexin-degrading bacterium strain AB-1, characterized in that: The Latin name of the cephalexin-degrading bacteria AB-1 is Escherichia coli AB-1, and the preservation number is CCTCC NO: M 20241312.
2. The cephalexin-degrading bacterium AB-1 according to claim 1, characterized in that: The cephalexin-degrading bacteria AB-1 is Escherichia coli.
3. Use of the cephalexin-degrading bacterium AB-1 according to any one of claims 1 to 2 in degrading cephalexin.
4. Use of the cephalexin-degrading bacterium AB-1 according to any one of claims 1 to 2 in the preparation of a cephalexin agent.
5. Use of the cephalexin-degrading bacterium AB-1 according to any one of claims 1 to 2 in remediating an environment contaminated by cephalexin.
6. The use according to claim 5, characterized in that: The invention discloses an application of the cephalexin-degrading bacteria AB-1 in degrading the residual cephalexin in farm manure.
Citation Information
Cited By
Inconoidea virens DLW198 and application thereof
CN120574721A
Gluconobacter suboxydans dlw198 and application thereof
CN120574721B
